Q2 2024 EPS Estimates for Bruker Co. Reduced by Leerink Partnrs (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Research analysts at Leerink Partnrs lowered their Q2 2024 earnings per share estimates for Bruker in a note issued to investors on Thursday, May 2nd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $0.54 for the quarter, down from their prior estimate of $0.59. The consensus estimate for Bruker’s current full-year earnings is $2.82 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2024 earnings at $0.78 EPS, Q4 2024 earnings at $0.98 EPS, FY2024 earnings at $2.83 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.72 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $1.20 EPS and FY2026 earnings at $4.02 EPS.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The firm had revenue of $721.70 million during the quarter, compared to the consensus estimate of $729.88 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $0.64 earnings per share.

BRKR has been the subject of a number of other reports. Stifel Nicolaus raised their price target on Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a research note on Wednesday, February 14th. Citigroup raised their price objective on Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. JPMorgan Chase & Co. raised Bruker from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $60.00 to $90.00 in a research report on Wednesday, February 14th. UBS Group raised their price objective on Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, The Goldman Sachs Group raised their price objective on Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $84.86.

Bruker Stock Up 3.5 %

BRKR stock opened at $72.52 on Monday. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95. The business has a 50 day moving average price of $87.16 and a two-hundred day moving average price of $75.34. The company has a market cap of $10.54 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 1.73 and a beta of 1.22. Bruker has a twelve month low of $53.79 and a twelve month high of $94.86.

Institutional Trading of Bruker

Several hedge funds have recently added to or reduced their stakes in BRKR. Envestnet Portfolio Solutions Inc. raised its holdings in Bruker by 3.3% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 13,606 shares of the medical research company’s stock valued at $1,278,000 after acquiring an additional 432 shares in the last quarter. Duality Advisers LP raised its holdings in Bruker by 12.5% in the 1st quarter. Duality Advisers LP now owns 8,619 shares of the medical research company’s stock valued at $810,000 after acquiring an additional 958 shares in the last quarter. Texas Permanent School Fund Corp raised its holdings in Bruker by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 81,161 shares of the medical research company’s stock valued at $7,624,000 after acquiring an additional 1,050 shares in the last quarter. Larson Financial Group LLC acquired a new position in Bruker in the 1st quarter valued at $178,000. Finally, Retirement Systems of Alabama raised its holdings in Bruker by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 116,451 shares of the medical research company’s stock valued at $10,939,000 after acquiring an additional 304 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Hermann Fritz Requardt sold 15,000 shares of Bruker stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now directly owns 23,147 shares of the company’s stock, valued at approximately $2,084,618.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 28.30% of the stock is currently owned by insiders.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were issued a dividend of $0.05 per share. The ex-dividend date was Thursday, February 29th. This represents a $0.20 annualized dividend and a yield of 0.28%. Bruker’s payout ratio is currently 7.27%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.